The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).
The study will collect data from eligible patients (six total) and physicians (six total) from one-on-one qualitative interviews and eligible patients from online surveys. Approximately 330 patients with PC will be recruited to complete the online DCE survey.
Study Type
OBSERVATIONAL
Enrollment
374
No investigational drug will be administered to participants in this study.
Analysis Group, Inc.
Boston, Massachusetts, United States
Patients' Preference weights for different treatment attributes
Preference data will be collected via online survey questionnaires designed using DCE method.
Time frame: Up to 1 day
Patients' Overall Preference for a specific treatment profile (NHT +/- ADT or ADT monotherapy)
Preference data will be collected via online survey questionnaires designed using DCE method.
Time frame: Up to 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.